Integration of genomic analysis and transcript expression of ABCC8 and KCNJ11 in focal form of congenital hyperinsulinism

被引:4
|
作者
Wieland, Ilse [1 ]
Schanze, Ina [1 ]
Felgendreher, Ina Marianti [1 ]
Barthlen, Winfried [2 ]
Vogelgesang, Silke [3 ]
Mohnike, Klaus [4 ]
Zenker, Martin [1 ]
机构
[1] Univ Magdeburg, Univ Hosp Otto von Guericke, Inst Human Genet, Magdeburg, Germany
[2] Univ Bielefeld, Univ Hosp OWL, Protestant Hosp Bethel Fdn, Dept Pediat Surg, Bielefeld, Germany
[3] Univ Greifswald, Univ Med, Inst Pathol, Greifswald, Germany
[4] Univ Magdeburg, Univ Hosp Otto von Guericke, Dept Pediat, Magdeburg, Germany
来源
关键词
ABCC8; Achaete-scute complex homolog 2; CHI; KCNJ11; UPD; 11p; IMPRINTED; 11P15; REGION; MUTATION; GENE; HYPOGLYCEMIA; MANAGEMENT; ISODISOMY;
D O I
10.3389/fendo.2022.1015244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe focal form of CHI is caused by an autosomal recessive pathogenic variant affecting the paternal homologue of genes ABCC8 or KCNJ11 and a second somatic event specifically occurring in the affected islet of Langerhans. The approach of this study was to integrate the genetic changes occurring in pancreatic focal lesions of CHI at the genomic and transcriptional level. Research Design and MethodsPatients receiving therapeutic surgery and with proven ABCC8 or KCNJ11 pathogenic variants were selected and analyzed for loss of heterozygosity (LOH), changes in copy number and uniparental disomy (UPD) on the short am of chromosome 11 by molecular microarray analysis and methylation-specific MLPA. Gene expression was analyzed by RT-PCR and Massive Analysis of cDNA Ends (MACE). ResultsBoth genes, ABCC8 and KCNJ11, are located in proximity to the Beckwith-Wiedemann (BWS) imprinting control region on chromosome 11p15. Somatic paternal uniparental isodisomy (UPD) at chromosome 11p was identified as second genetic event in focal lesions resulting in LOH and monoallelic expression of the mutated ABCC8/KCNJ11 alleles. Of five patients with samples available for microarray analysis, the breakpoints of UPD on chromosome 11p were different. Samples of two patients were analyzed further for changes in gene expression. Profound downregulation of growth suppressing genes CDKN1 and H19 was detected in focal lesions whereas growth promoting gene ASCL2 and pancreatic transcription factors of the endocrine cell lineage were upregulated. ConclusionsPaternal UPD on the short arm of chromosome 11 appears to be the major second genetic event specifically within focal lesions of CHI but no common breakpoint for UDP can be delineated. We show for the first time upregulation of growth promoting ASCL2 (achaete-scute homolog 2) suggestive of a driving factor in postnatal focal expansion in addition to downregulation of growth suppressing genes CDKN1C and H19.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers
    Stanik, Juraj
    Gasperikova, Daniela
    Paskova, Magdalena
    Barak, Lubomir
    Javorkova, Jana
    Jancova, Emilia
    Ciljakova, Miriam
    Hlava, Peter
    Michalek, Jozef
    Flanagan, Sarah E.
    Pearson, Ewan
    Hattersley, Andrew T.
    Ellard, Sian
    Klimes, Iwar
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04): : 1276 - 1282
  • [42] Hepatoblastoma in a child with a paternally-inherited ABCC8 mutation and mosaic paternal uniparental disomy 11p causing focal congenital hyperinsulinism
    Calton, Elizabeth A.
    Temple, I. Karen
    Mackay, Deborah J. G.
    Lever, Margaret
    Ellard, Sian
    Flanagan, Sarah E.
    Davies, Justin H.
    Hussain, Khalid
    Gray, Juliet C.
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2013, 56 (02) : 114 - 117
  • [43] Congenital, transient or focal hyperinsulinism, adult hypoglycaemia, gestational diabetes and insulin resistance caused by heterozygous inhibiting mutations in KCNJ11
    Brusgaard, K
    Christesen, H
    Carlsson, A
    Sivaprasadarao, R
    Ivarsson, S
    Brock-Jacobsen, B
    DIABETOLOGIA, 2005, 48 : A114 - A114
  • [44] CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients
    Klen, Jasna
    Dolzan, Vita
    Janez, Andrej
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (04) : 421 - 428
  • [45] CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients
    Jasna Klen
    Vita Dolžan
    Andrej Janež
    European Journal of Clinical Pharmacology, 2014, 70 : 421 - 428
  • [46] Update of Mutations in the Genes Encoding the Pancreatic Beta-Cell KATP Channel Subunits Kir6.2 (KCNJ11) and Sulfonylurea Receptor 1 (ABCC8) in Diabetes Mellitus and Hyperinsulinism
    Flanagan, Sarah E.
    Clauin, Severine
    Bellanne-Chantelot, Christine
    de Lonlay, Pascale
    Harries, Lorna W.
    Gloyn, Anna L.
    Ellard, Sian
    HUMAN MUTATION, 2009, 30 (02) : 170 - 180
  • [47] Effectiveness of Calcium Channel Blocker Nifedipine in Children with Hyperinsulinaemic Hypoglycaemia Due to Genetically Proven Mutations in the ABCC8/KCNJ11/GCK Genes
    Gueemes, Maria
    Shah, Pratik
    Silvera, Shavel
    Morgan, Kate
    Gilbert, Clare
    Hinchey, Louise
    Hussain, Khalid
    HORMONE RESEARCH IN PAEDIATRICS, 2016, 86 : 349 - 349
  • [48] KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment
    Song, Jingwen
    Yang, Yunzhong
    Mauvais-Jarvis, Franck
    Wang, Yu-Ping
    Niu, Tianhua
    BMC MEDICAL GENETICS, 2017, 18
  • [49] Variability of type 1 diabetes predisposing genes in anti-islet autoantibody seroconversion observed in PNDM caused by mutations in the KCNJ11 and ABCC8
    Gach, Agnieszka
    Malecki, Maciej T.
    Klich, Izabela
    Wyka, Krystyna
    Heinrich, Agnieszka
    Borowiec, Maciej
    Sieradzki, Jacek
    Mlynarski, Wojciech M.
    DIABETES, 2008, 57 : A320 - A320
  • [50] ABCC8 (SUR1) and KCNJ11 (KIR6.2) mutations in persistent hyperinsulinemic hypoglycemia of infancy and evaluation of different therapeutic measures
    Darendeliler, F
    Fournet, JC
    Bas, F
    Junien, C
    Gross, MS
    Bundak, R
    Saka, N
    Günöz, H
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2002, 15 (07): : 993 - 1000